Clinical Trials
271 trialsPacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
National Institutes of Health Clinical Center (CC)
FORWARD
CareDx
Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS
Ruijin Hospital
Personalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
National Cancer Institute (NCI)
Haplo-Cord HSCT for AML/MDS
Fujian Medical University Union Hospital
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
National Cancer Institute (NCI)
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Medical College of Wisconsin
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Dresden MDS Registry With an Accompanying Biomaterial Collection
Technische Universität Dresden
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc.
UHKT-PTC-TMI-1
Institute of Hematology and Blood Transfusion, Czech Republic
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Children's Hospital of Philadelphia
A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients
The First Affiliated Hospital of Soochow University
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
National Cancer Institute (NCI)
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
WATCH Tranfuse
University of Oxford
Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia
Nationwide Children's Hospital
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
ACCELERATE
Center for International Blood and Marrow Transplant Research
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Memorial Sloan Kettering Cancer Center
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
M.D. Anderson Cancer Center
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
Apollo Therapeutics Ltd
Romiplostim N01 for Platelet Recovery After Haploidentical HSCT
First Affiliated Hospital of Zhejiang University
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Cullgen (Shanghai),Inc
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Masonic Cancer Center, University of Minnesota
Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation
Institute of Hematology & Blood Diseases Hospital, China
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Fred Hutchinson Cancer Center
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
ARCE Therapeutics, Inc.
A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
ARCE Therapeutics, Inc.
RAFA
Children's Hospital Medical Center, Cincinnati
AB-CliniMACs
Children's Hospital of Philadelphia
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Incyte Corporation
Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation
University Hospital Tuebingen
RELEVANT
Technische Universität Dresden
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
Masonic Cancer Center, University of Minnesota
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Oral-ATO for TP53-mutated Myeloid Malignancies
The University of Hong Kong
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Fred Hutchinson Cancer Center
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer
City of Hope Medical Center
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Thomas Jefferson University